Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data
1. SLXN stock surged 14.83% to $5.15, high trading volume observed. 2. New preclinical data show SIL204 effectively targets pancreatic cancer. 3. Statistically significant tumor burden reductions noted in major metastatic sites. 4. Phase 2/3 trials scheduled for early 2026 with regulatory submissions approaching. 5. Public offering of shares and warrants priced at $4.